Alnylam Pharmaceuticals Unveils 2024 Corporate Responsibility Report, Showcasing Impact Across ESG Pillars
Alnylam Pharmaceuticals, the industry leader in RNA interference (RNAi) therapeutics, has published its 2024 Corporate Responsibility Report, reaffirming its commitment to science, sustainability, equity, and ethical business conduct. Under the overarching theme, “Accepting Challenges to Improve the Health of Humanity,” this year’s report provides a comprehensive view of the company’s initiatives and progress across six strategic pillars of corporate responsibility.
The report paints a vivid picture of how Alnylam is evolving beyond its role as a biotechnology innovator to become a model for corporate accountability. The company’s dedication spans multiple fronts—from equitable patient access and environmental stewardship to an inclusive workplace and groundbreaking scientific discovery.
CEO Statement: A Dual Commitment to Innovation and Responsibility
Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam, emphasized the company’s dual mission of advancing medical innovation while building a healthier, fairer, and more sustainable world.
“As we continue to lead the way in RNAi innovation, there is a profound opportunity in front of us to shape the future of medicine and impact the lives of millions of patients,” said Dr. Greenstreet. “At Alnylam, we believe that making history means advancing groundbreaking science while shaping a healthier, more equitable, and sustainable future for all.”
This sentiment underscores Alnylam’s belief that scientific innovation and corporate responsibility are not mutually exclusive but are in fact mutually reinforcing.
Environmental Responsibility: Transparent Climate Action and Renewable Energy Adoption
A major focus of this year’s report is environmental sustainability, with Alnylam publishing new and independently verified data on its greenhouse gas (GHG) emissions and resource consumption. The company provided multiyear disclosures for Scope 1, 2, and 3 emissions, offering stakeholders a transparent view of its environmental footprint and progress toward reduction targets.
Highlights from the environmental section include:
- Verified emissions data: Alnylam’s emissions tracking was validated by third-party experts, covering direct (Scope 1), indirect (Scope 2), and value-chain-related (Scope 3) emissions.
- Energy use and water conservation: The report includes detailed metrics on energy consumption, water usage, and waste generation, all of which contribute to its long-term environmental goals.
- 100% renewable energy use: The company’s manufacturing sites at Norton and Alewife now operate fully on renewable electricity, a milestone that reflects Alnylam’s commitment to clean energy integration across operations.
This year’s data-driven approach marks an important step in operationalizing sustainability and aligns with global climate objectives, including those outlined in the Paris Agreement.
Patient Access: Making Breakthrough Therapies More Reachable
At the heart of Alnylam’s mission is its Patient Access Philosophy, which continues to evolve to address unmet needs and broaden the reach of RNAi-based therapies. In 2024, the company reexamined and refined the core principles guiding this initiative to ensure they remain responsive to changing patient needs, regulatory landscapes, and health system dynamics.
Key developments include:
- Philosophy refresh: The updated Patient Access Philosophy reflects a renewed focus on value, impact, outcomes, and accountability. Alnylam is working to deliver better health results while actively measuring the social and economic benefits of its treatments.
- Quantitative and qualitative metrics: The company published robust data to illustrate how its access programs translate into real-world outcomes, including metrics on treatment affordability, speed to diagnosis, and regional disparities.
- Global reach: Alnylam’s efforts extend beyond the U.S. and Europe, with initiatives in low- and middle-income countries to support early diagnosis, physician education, and access to RNAi medicines through compassionate use and managed access programs.
By anchoring access programs in both data and empathy, Alnylam continues to ensure that the transformative power of RNAi reaches those who need it most.
Health Equity: Expanding the Impact of the Alnylam Challengers Initiative
Alnylam has deepened its focus on health equity through the expansion of the Alnylam Challengers initiative, a global program that partners with social entrepreneurs and community-based organizations to address systemic disparities in healthcare.
In 2024, the company highlighted:
- Collaborations in the U.S. and Europe: Through partnerships with local nonprofits and innovators, Alnylam supports community-driven solutions to address the root causes of health inequity.
- Education and workforce training: Initiatives launched under the Challengers banner include mentorship programs, vocational training, and educational tools aimed at empowering underrepresented populations.
- Long-term community benefits: Alnylam’s efforts are not short-term interventions but are designed to yield sustainable improvements in health outcomes and socioeconomic stability.
This work reflects Alnylam’s belief that biotechnology companies have a role not only in treating disease but also in addressing the social determinants of health.
People and Culture: Building an Inclusive, Empowered Workforce
Alnylam’s internal culture is another pillar of its corporate responsibility strategy. In 2024, the company strengthened its investment in employees, focusing on inclusion, personal growth, and well-being.
Highlights from this section of the report include:
- Employee Resource Networks (ERNs): Alnylam has expanded its ERNs to foster community among employees of diverse backgrounds, interests, and identities. These groups play a key role in internal advocacy, mentorship, and education.
- Enhanced benefits and recruitment: Alnylam expanded family leave policies, mental health support, and hybrid work options to meet the evolving needs of its workforce. Recruitment strategies were also revamped to attract talent from nontraditional backgrounds and underrepresented communities.
- Culture survey results: The company’s latest Employee Culture Survey yielded strong results, with 88% of respondents saying they feel accepted and treated fairly. This data point speaks volumes about Alnylam’s inclusive and respectful work environment.
Alnylam views its employees as the foundation of its mission, and the company’s investments in culture are designed to ensure long-term retention, satisfaction, and innovation.
Advancing Innovative Science: Progress in RNAi Research
While the Corporate Responsibility Report primarily focuses on ESG initiatives, Alnylam also used the opportunity to reinforce its scientific leadership in RNAi—a field the company has pioneered for over two decades.
The report touches on:
- Pipeline development: Alnylam continues to advance a growing pipeline of RNAi therapeutics for both rare and common diseases, including investigational treatments for cardiometabolic, hepatic, and central nervous system conditions.
- Research transparency: The company upholds strong standards for clinical trial disclosure, publication, and ethical conduct in research—key components of scientific responsibility.
- Collaboration: Alnylam is increasingly collaborating with academic institutions, advocacy groups, and peer biotech companies to ensure that science advances in an open, ethical, and patient-centered way.
These scientific milestones are directly tied to Alnylam’s broader mission to transform lives through RNAi, and the report underscores how innovation and responsibility can go hand in hand.
A Blueprint for Purpose-Driven Growth
Alnylam’s 2024 Corporate Responsibility Report is more than a retrospective; it serves as a strategic blueprint for the company’s future direction. By outlining measurable goals, sharing transparent progress updates, and weaving together science with social good, Alnylam presents itself as a model for purpose-driven growth in the biopharmaceutical sector.
As the company prepares for its next chapter in advancing RNAi therapeutics, it remains firmly rooted in the principles of equity, sustainability, and shared prosperity.
